A protein called PDIA5 controls how much glucose the liver produces, and boosting it in mice with diabetes significantly improved their blood sugar levels and insulin sensitivity. According to Gram Research analysis, when PDIA5 was increased in diabetic mice, it protected another protein called ATF6, which naturally suppresses the genes responsible for glucose production. This discovery identifies PDIA5 as a potential new drug target for treating type 2 diabetes, though human studies are needed before any treatment becomes available.
Scientists have discovered that a protein called PDIA5 plays a crucial role in controlling blood sugar levels in the liver. According to Gram Research analysis, when this protein is increased in mice with diabetes, it helps reduce high blood sugar and improves how the body uses insulin. The research shows that PDIA5 works by protecting another protein called ATF6, which naturally suppresses the liver’s glucose production. This finding could lead to new treatments for type 2 diabetes by targeting this specific protein pathway, offering hope for millions of people struggling with blood sugar control.
Key Statistics
A 2026 research study published in Diabetologia found that increasing PDIA5 in the livers of high-fat diet-fed mice significantly reduced blood glucose levels and improved glucose tolerance compared to control mice.
According to the 2026 study, hepatic PDIA5 expression was significantly reduced in both people with metabolic dysfunction-associated steatotic liver disease and in mouse models of type 2 diabetes.
The research demonstrated that PDIA5 stabilizes the protein ATF6 by shielding it from the E3 ubiquitin ligase SYVN1, preventing its degradation and allowing ATF6 to suppress gluconeogenic genes that produce glucose.
The Quick Take
- What they studied: Whether a protein called PDIA5 controls how much glucose (sugar) the liver makes, and whether boosting this protein could help treat type 2 diabetes
- Who participated: Male mice fed a high-fat diet to mimic type 2 diabetes, female mice with genetic modifications, liver cells from mice and humans, and liver tissue samples from people with fatty liver disease
- Key finding: When researchers increased PDIA5 in the livers of diabetic mice, the mice’s blood sugar levels improved significantly and their bodies became better at using insulin
- What it means for you: This research identifies a new target for diabetes drugs. While these are early findings in animals, they suggest future treatments could work by boosting PDIA5 to help the liver control blood sugar better. Talk to your doctor about how this might affect diabetes treatment options in the future
The Research Details
Researchers used multiple approaches to understand how PDIA5 works. First, they examined liver tissue from people with fatty liver disease and from mice with diabetes, finding that PDIA5 levels were lower than normal. Next, they used a technique called adenoviral overexpression to increase PDIA5 in the livers of mice eating a high-fat diet, then measured how well these mice controlled their blood sugar using standard glucose and insulin tests.
To understand the mechanism, the team conducted detailed laboratory experiments using liver cells and other cell types. They used techniques like co-immunoprecipitation (a method to identify proteins that stick together) and chromatin immunoprecipitation (a method to see where proteins bind to DNA) to trace exactly how PDIA5 affects other proteins involved in glucose production.
Finally, they confirmed their findings by studying mice that had the Pdia5 gene completely removed. These knockout mice developed worse glucose problems when fed a high-fat diet, proving that PDIA5 is necessary for normal blood sugar control.
This research approach is important because it moves from observation (PDIA5 is low in diabetic livers) to mechanism (how PDIA5 actually works) to proof of necessity (what happens when it’s missing). This three-step approach gives scientists confidence that PDIA5 is truly important for controlling blood sugar, not just coincidentally related to diabetes. Understanding the exact molecular pathway also helps researchers design drugs that could safely target this system.
This study was published in Diabetologia, a top-tier peer-reviewed journal specializing in diabetes research. The researchers used multiple complementary techniques and confirmed their findings in different cell types and animal models. The use of knockout mice (animals genetically engineered to lack PDIA5) provides strong evidence that this protein is necessary for normal glucose control. However, because the main experiments were conducted in mice and cell cultures rather than humans, the findings need to be tested in human clinical trials before becoming a treatment.
What the Results Show
When PDIA5 was increased in the livers of high-fat diet-fed mice, their blood sugar levels dropped significantly and their glucose tolerance improved. The mice also showed better insulin sensitivity, meaning their bodies responded more effectively to insulin. These improvements occurred because increased PDIA5 suppressed the expression of two key genes (Pck1 and G6pc1) that control glucose production in the liver.
The mechanism behind this improvement is elegant: PDIA5 physically attaches to and protects a protein called ATF6. Normally, ATF6 gets marked for destruction by another protein called SYVN1, which tags it with ubiquitin (a cellular destruction signal). By shielding ATF6 from this destruction process, PDIA5 keeps more ATF6 available to suppress the genes that make glucose.
When researchers removed ATF6 from cells, PDIA5 could no longer improve glucose metabolism, proving that ATF6 is essential for PDIA5’s beneficial effects. This finding confirms that the PDIA5-ATF6 interaction is the core mechanism responsible for controlling blood sugar.
The research also revealed that PDIA5 affects the PERK-TRB3 signaling pathway, which is involved in how cells respond to stress in the endoplasmic reticulum (a cellular structure that processes proteins). By stabilizing ATF6, PDIA5 enhances hepatic insulin sensitivity, meaning the liver becomes more responsive to insulin’s signals. Additionally, the study found that PDIA5 prevents the co-activator protein CRTC2 from reaching the promoter regions of genes that make glucose, providing another layer of control over glucose production.
Previous research has shown that ATF6 is important for controlling glucose production, but scientists didn’t fully understand how ATF6 levels are regulated in the liver. This study fills that gap by identifying PDIA5 as the key protein that keeps ATF6 stable. The discovery also connects hepatic lipid overload (fat accumulation in the liver) to glucose dysregulation through a specific molecular pathway, providing a more complete picture of how fatty liver disease contributes to type 2 diabetes. This represents a significant advance in understanding the link between liver fat and blood sugar problems.
The main limitation is that these experiments were primarily conducted in mice and cultured cells, not in humans. Mouse metabolism doesn’t always translate directly to human metabolism, so these findings need confirmation in human studies. The research focused on male mice in most experiments, so it’s unclear whether the same mechanisms apply equally to females. Additionally, the study doesn’t address whether PDIA5 levels can be safely and effectively increased in humans, or what side effects such an increase might cause. Finally, while the research identifies PDIA5 as a therapeutic target, developing a drug that safely boosts PDIA5 activity remains a future challenge.
The Bottom Line
Based on this research, PDIA5 emerges as a promising target for new type 2 diabetes treatments. However, these findings are preliminary and based on animal studies. Current recommendations remain unchanged: maintain a healthy weight, exercise regularly, eat a balanced diet, and follow your doctor’s guidance on diabetes management. In the future, drugs designed to boost PDIA5 or stabilize ATF6 may become available as additional treatment options. Discuss with your healthcare provider how emerging therapies might fit into your personal diabetes management plan.
People with type 2 diabetes or those at risk for developing it should follow this research, as it could lead to new treatment options. People with fatty liver disease (MASLD) should also pay attention, since the study shows a connection between liver fat and blood sugar control. Healthcare providers treating diabetes should be aware of this emerging therapeutic target. However, people without diabetes or liver disease don’t need to take action based on this research alone. Pregnant women and children should wait for further human studies before any potential treatments based on this work become available.
If PDIA5-targeting drugs are developed, it typically takes 5 to 10 years from laboratory discovery to human clinical trials, and another 5 to 10 years for FDA approval and availability. So realistic expectations are that any treatment based on this research would not be available for at least 10 to 15 years. In the meantime, current diabetes treatments remain the most reliable option for managing blood sugar.
Frequently Asked Questions
What is PDIA5 and why does it matter for diabetes?
PDIA5 is a protein that controls how much glucose the liver produces. A 2026 study found that people with type 2 diabetes have lower PDIA5 levels. Boosting PDIA5 in diabetic mice improved their blood sugar control, suggesting it could become a new diabetes treatment target.
How does PDIA5 help control blood sugar?
PDIA5 protects another protein called ATF6, which naturally suppresses genes that make glucose. By keeping ATF6 stable, PDIA5 prevents the liver from producing too much glucose, helping maintain normal blood sugar levels.
When will PDIA5-based diabetes treatments be available?
These findings are from animal studies, so human clinical trials are needed first. Realistically, any PDIA5-targeting drug would take 10 to 15 years to develop, test, and gain FDA approval. Current diabetes treatments remain the most reliable option today.
Does this research apply to people with fatty liver disease?
Yes. The study found that people with fatty liver disease have reduced PDIA5 levels. Since the research shows PDIA5 controls glucose production, it suggests a connection between liver fat and blood sugar problems, making this relevant for people with both conditions.
What should I do differently based on this research?
No immediate changes are needed, but you can reduce high-fat foods and increase exercise, which help reduce liver fat. Continue following your doctor’s diabetes management plan. Discuss this emerging research with your healthcare provider at your next appointment.
Want to Apply This Research?
- Track your fasting blood glucose levels weekly and record them alongside your diet composition (especially fat intake) and exercise minutes. Over 8 to 12 weeks, look for trends in how your blood sugar responds to high-fat meals versus balanced meals. This personal data will help you understand your individual glucose patterns and prepare you to discuss new treatment options with your doctor when they become available.
- Start reducing high-fat foods in your diet, particularly saturated fats, since this research highlights the connection between liver fat accumulation and blood sugar problems. Use the app to log your daily fat intake and set a goal to reduce it by 10 to 15% over the next month. Pair this with 150 minutes of moderate exercise weekly, which helps reduce liver fat and improve insulin sensitivity.
- Set up monthly reminders to check your weight, waist circumference, and energy levels. Use the app to track these metrics alongside your blood glucose readings and dietary choices. Create a simple dashboard showing your progress over 3 to 6 months. Share this data with your healthcare provider at your next appointment to discuss whether your current management strategy is working or needs adjustment.
This article summarizes research findings from animal and cell culture studies. The results have not yet been tested in humans. PDIA5-targeting treatments are not currently available and remain in early research stages. This information is for educational purposes only and should not replace professional medical advice. If you have type 2 diabetes or concerns about your blood sugar, consult your healthcare provider about appropriate treatment options. Do not make changes to your diabetes management based solely on this research. Always discuss new therapeutic approaches with your doctor before considering them for your personal health care.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.